Announcements Trials
Browse Landscape

Phase

Phase 2 1

Status

Active not recruiting 1

Sponsor Class

NIH 1

Study Type

Interventional 1

Sponsor

Cancer Type

Myeloid 1Lymphoid 1Genitourinary 1Gastrointestinal 1CNS 1

Conditions

Urinary Bladder Neoplasms 6Non-Muscle Invasive Bladder Neoplasms 5Glioma 4Carcinoma, Transitional Cell 3Wilms Tumor 2Urothelial Cancer 2Rhabdoid Tumor 2Prostatic Neoplasms 2Neuroectodermal Tumors, Primitive, Peripheral 2Neuroblastoma 2Multiple Myeloma 2Medulloblastoma 2Lymphoma, Non-Hodgkin 2Lymphoma 2Histiocytosis, Langerhans-Cell 2Hepatoblastoma 2Ependymoma 2Central Nervous System Neoplasms 2Xanthogranuloma, Juvenile 1Uterine Neoplasms 1Uterine Cervical Neoplasms 1Urethral Neoplasms 1Ureteral Neoplasms 1Thyroid Neoplasms 1Stomach Neoplasms 1Sarcoma, Ewing 1Sarcoma 1Rhabdomyosarcoma 1Rectal Neoplasms 1Pancreatic Neoplasms 1

Interventions

Specimen Handling 2Magnetic Resonance Spectroscopy 2pembrolizumab 1palbociclib 1erdafitinib 1X-Rays 1Phantoms, Imaging 1Nuclear Medicine Department, Hospital 1Diffusion Tensor Imaging 1Biopsy 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

1 trials
RecentStart dateEnrollment
Familial ependymoma × erdafitinib × 1 year × Clear all
NCT03210714 2026-06-01

Erdafitinib in Treating Patients With Relapsed or Refractory Advanced Solid Tumors, Non-Hodgkin Lymphoma, or Histiocytic Disorders With FGFR Mutations (A Pediatric MATCH Treatment Trial)

National Cancer Institute (NCI)

Phase 2 Active not recruiting
20 enrolled 10 charts
CNSGastrointestinalGenitourinaryLymphoidMyeloid

Familial ependymoma, Ependymoma, Glioma, Histiocytosis, Langerhans-Cell, Lymphoma, Non-Hodgkin, Medulloblastoma, Wilms Tumor, Neuroblastoma, Central Nervous System Neoplasms, Hepatoblastoma, Neuroectodermal Tumors, Primitive, Peripheral, Rhabdoid Tumor

Data powered by HemOnc (CC BY 4.0) Colophon âš¡